Expression of CD55, CD59, CD46 and CD35 in Peripheral Blood Cells from Rheumatoid Arthritis Patients


Evidences point that complement activation plays a role in rheumatoid arthritis (RA). In this context, expression of the CReg was investigated on white cells from peripheral blood of 30 RA patients and 30 healthy controls. Using flow cytometric analyses the relative fluorescence intensities (MFI) of Cregs were determined. CD59 MFI was significantly increased in RA cells comparing to controls, respectively: lymphocytes 36.8 versus 27.07; monocytes 32.0 versus 21.37; and granulocytes: 84.6 versus 66.1 (p < 0.05). Interestingly, no difference was observed on the MFI to CD55, CD46 and CD35 in these cells. These data indicate an overexpression of CD59 in all the peripheral blood cells of RA patients, perhaps due to an increased synthesis for compensatory mechanisms because of complement activation, inflammatory status or other factors associated with the disease.

Share and Cite:

A. Piccoli, A. Alegretti, L. Schneider, P. Lora, C. Brenol and R. Xavier, "Expression of CD55, CD59, CD46 and CD35 in Peripheral Blood Cells from Rheumatoid Arthritis Patients," Open Journal of Rheumatology and Autoimmune Diseases, Vol. 4 No. 1, 2014, pp. 69-73. doi: 10.4236/ojra.2014.41011.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] C. A. Smith and F. C. Arnett, “Epidemiologic Aspects of Rheumatoid Arthritis. Current Immunogenetic Approach,” Clinical Orthopaedics and Related Research, Vol. 265, 1991, pp. 23-35.
[2] M. Okroj, D. Heinegard, R. Holmdahl and A. M. Blom, “Rheumatoid Arthritis and the Complement System,” Annals of Medicine, Vol. 39, No. 7, 2007, pp. 517-530.
[3] J. J. Goronzy and C. M. Weyand, “Rheumatoid Arthritis,” Immunological Reviews, Vol. 204, 2005, pp. 55-73.
[4] P. F. Zipfel and C. Skerka, “Complement Regulators and Inhibitory Proteins,” Nature Reviews Immunology, Vol. 9, No. 10, 2009, pp. 729-740.
[5] E. Wagner and M. M. Frank, “Therapeutic Potential of Complement Modulation,” Nature Reviews, Vol. 9, No. 1, 2010, pp. 43-56.
[6] A. D. Crockard, J. M. Thompson, S. J. Mcbride, J. D. Edgar, T. A. Mcneill and A. L. Bell, “Markers of Inflammatory Activation: Upregulation of Complement Receptors Cr1 and Cr3 on Synovial Fluid Neutrophils from Patients with Inflammatory Joint Disease,” Clinical Immunology and Immunopathology, Vol. 65, No. 2, 1992, pp. 135-142.
[7] J. Jones, I. Laffafian, A. M. Cooper, B. D. Williams and B. P. Morgan, “Expression of Complement Regulatory Molecules and Other Surface Markers on Neutrophils from Synovial Fluid and Blood of Patients with Rheumatoid Arthritis,” British Journal of Rheumatology, Vol. 33, No. 8, 1994, pp. 707-712.
[8] D. Mccarthy, M. J. Taylor, J. Bernhagen, J. D. Perry and A. S. Hamblin, “Leucocyte Integrin and Cr1 Expression on Peripheral Blood Leucocytes of Patients with Rheumatoid Arthritis,” Annals of the Rheumatic Diseases, Vol. 51, No. 3, 1992, pp. 307-312.
[9] I. Torsteinsdottir, N. G. Arvidson, R. Hallgren and L. Hakansson, “Monocyte Activation in Rheumatoid Arthritis (Ra): Increased Integrin, Fc Gamma and Complement Receptor Expression and the Effect of Glucocorticoids,” Clinical and Experimental Immunology, Vol. 115, 1999, pp. 554-560.
[10] S. J. Gadd, T. Felzmann, O. Majdic, D. Maurer, P. Petera, W. J. Chen and A. L. Et, “Phenotypic Analysis of Functionally Associated Molecules on Peripheral Blood and Synovial Fluid Monocytes from Arthritis Patients,” Rheumatology International, Vol. 12, No. 4, 1992, pp. 153-157.
[11] F. C. Arnett, S. M. Edworthy, D. A. Bloch, D. J. Mcshane, J. F. Fries, N. S. Cooper, et al., “The American Rheumatism Association 1987 Revised Criteria for the Classification of Rheumatoid Arthritis,” Arthritis & Rheumatism, Vol. 31, No. 3, 1988, pp. 315-324.
[12] A. P. Alegretti, T. Mucenic, J. Merzoni, G. A. Faulhaber, L. M. Silla and R. M. Xavier, “Expression of CD55 and CD59 on Peripheral Blood Cells from Systemic Lupus Erythematosus (Sle) Patients,” Cellular Immunology, Vol. 265, No. 2, 2010, pp. 127-132.
[13] Y. T. Konttinen, A. Ceponis, S. Meri, A. Vuorikoski, P. Kortekangas, T. Sorsa, et al., “Complement in Acute and Chronic Arthritides: Assessment of C3c, C9, and Protectin (Cd59) in Synovial Membrane,” Annals of the Rheumatic Diseases, Vol. 55, No. 12, 1996, pp. 888-894.
[14] C. Kemper, J. W. Verbsky, J. D. Price and J. P. Atkinson, “T-Cell Stimulation and Regulation: With Complements from Cd46,” Immunologic Research, Vol. 32, No. 1-3, 2005, pp. 31-43.
[15] J. Petranka, J. Zhao, J. Norris, N. B. Tweedy, R. E. Ware, P. J. Sims, et al., “Structure-Function Relationships of the Complement Regulatory Protein, Cd59,” Blood Cells, Molecules & Diseases, Vol. 22, No. 3, 1996, pp. 281-296.
[16] F. Lund-Johansen, J. Olweus, F. W. Symington, A. Arli, J. S. Thompson, R. Vilella, et al., “Activation of Human Monocytes and Granulocytes by Monoclonal Antibodies to Glycosylphosphatidylinositol-Anchored Antigens,” European Journal of Immunology, Vol. 23, No. 11, 1993, pp. 2782-2791.
[17] G. T. Venneker and S. S. Asghar, “Cd59: A Molecule Involved in Antigen Presentation as Well as Downregulation of Membrane Attack Complex,” Experimental and Clinical Immunogenetics, Vol. 9, No. 1, 1992, pp. 33-47.
[18] M. Deckert, J. Kubar and A. Bernard, “Cd58 and Cd59 Molecules Exhibit Potentializing Effects in T Cell Adhesion and Activation,” Journal of Immunology, Vol. 148, No. 3, 1992, pp. 672-677.
[19] P. E. Korty, C. Brando and E. M. Shevach, “Cd59 Functions as a Signal-Transducing Molecule for Human T Cell Activation,” Journal of Immunology, Vol. 146, No. 12, 1991, pp. 4092-4098.
[20] M. Mizuno, “A Review of Current Knowledge of the Complement System and the Therapeutic Opportunities in Inflammatory Arthritis,” Current Medicinal Chemistry, Vol. 13, No. 14, 2006, pp. 1707-1717.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.